KalVista Pharmaceuticals (FRA:4XC1) EV-to-EBITDA : -3.34 (As of May. 27, 2024)

KalVista Pharmaceuticals EV-to-EBITDA Chart

KalVista Pharmaceuticals Annual Data
	Trend	Dec14	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23
EV-to-EBITDA		Get a 7-Day Free Trial					-10.07	-3.21	-6.39	-1.61	-1.36

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-EBITDA	Get a 7-Day Free Trial															-1.03	-1.36	-2.04	-1.69	-3.88

Competitive Comparison of KalVista Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, KalVista Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's EV-to-EBITDA falls into.

KalVista Pharmaceuticals EV-to-EBITDA Calculation

KalVista Pharmaceuticals's EV-to-EBITDA for today is calculated as:

KalVista Pharmaceuticals's current Enterprise Value is €377.89 Mil.
KalVista Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-113.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals  (FRA:4XC1) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

KalVista Pharmaceuticals's PE Ratio for today is calculated as:

KalVista Pharmaceuticals's share price for today is €10.20.
KalVista Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.900.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

KalVista Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (FRA:4XC1) Business Description